Business · 1 sources covering this

New launches, chronic portfolio to maintain growth for Zydus Lifesciences

Strong domestic formulations, chronic therapies, new US launches and a complex-product pipeline have supported the rally, though valuations now stand above historical averages

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·1h ago
New launches, chronic portfolio to maintain growth for Zydus Lifesciences
Strong domestic formulations, chronic therapies, new US launches and a complex-product pipeline have supported the rally, though valuations now stand above historical averages
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/639d3691c5f4174d3c27477d89e2e5100f251756"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="New launches, chronic portfolio to maintain growth for Zydus Lifesciences"></iframe>

New launches, chronic portfolio to maintain growth for Zydus Lifesciences

How 1 sources are covering this

New launches, chronic portfolio to maintain growth for Zydus Lifesciences

More from Business

What are the objectives of the National PNG Drive 3.0? | Explained

'Judge cannot decide this case': Curative plea in SC seeks recall of earlier verdict on CEC, ECs appointment law

Redemption Complete! Parveen Hooda Beats Chen Nien-Chin To Clinch Asian Games Gold

Andhra commercial tax collections rise 18 pc

Reader

Trust & legal

Across the network